Poster Presentations: P1
published CSF total tau (T-Tau) cutoff values: T-Tau positive (n¼145, males¼72) and T-Tau negative (n¼63, males¼48) patients, characterized by CSF T-Tau values above or below the 93 pg/mL threshold, respectively. Voxel-based morphometry (VBM) was applied to compare whole-brain patterns of GM and WM volume in T-Tau positive and negative patients. Statistical analyses were performed by using SPM12 software. Age, gender, education, MMSE score, MRI field strength and intracranial volume were included as nuisance variables in the analysis. Results: T-Tau positive and negative patients were comparable in terms of age, dementia clinical severity, ApoE4 phenotype, and neuropsychological impairment. Only T-tau positive AD exhibited significant (FWE corrected) and extensive WM volume loss in bilateral medial temporal regions compared to CN, in particular in the parahyppocampal WM. When compared to T-tau negative AD, T-tau positive patients showed no GM volume reduction. Instead, they presented extensive WM atrophy in bilateral fornix, corona radiata and centrum semiovale (p550ng/l), 82 probable AD patients (National Institute on Aging-Alzheimer’s Association workgroups core criteria, high likelihood of AD pathophysiology based on CSF tau/amyloid-beta1-42 >.52ng/ l), and 26 CN (22 subjects with subjective memory complaints and 4 healthy controls, CSF amyloid-beta1-42 >550ng/l). Glucose metabolism was assessed using [18F]FDG-PET. Parametric images of standardized uptake value ratios (SUVr) using cerebellar grey matter as reference tissue were generated. First, we defined PCC hypometabolism based on the Receiver Operating Characteristic (ROC) separating AD from CN, to assess the relative prevalence of PCC hypometabolism in AD, bvFTD and CN. Second, we explored relationships between PCC metabolism and demographics (age, sex, and education), MiniMental State Examination (MMSE), neuropsychological tests, CSF biomarkers (amyloid-beta1-42, tau and phosphorylated tau), and APOE genotype within diagnostic groups using linear regression analyses or ANOVA where appropriate. Results: Mean age was 6367 (AD), 6568 (bvFTD) and 6168 (CN) years old. PCC [18F]FDG SUVr was CN > bvFTD > AD. Based on optimal discrimination of AD and CN, the PCC [18F]FDG SUVr cut-off was set at 1.052, resulting in PCC hypometabolism in 78% (AD), 33% (bvFTD), and 23% (CN). PCC [18F] FDG SUVr was associated with age in CN (beta6SE: -.0076.002, p¼.002) and bvFTD (beta6SE: -.0076.003, p¼.011), not in AD. Conclusions: PCC hypometabolism was present in 33% of bvFTD and 23% of CN. PCC [18F]FDG SUVr was associated with age in bvFTD and CN. In the context of diagnostic work-up of dementia, it is important to realize that PCC vulnerability is not restricted to AD, but could be present in bvFTD and normal aging.
P1-181
P1-180
HYPOMETABOLISM OF THE POSTERIOR CINGULATE CORTEX IS NOT RESTRICTED TO ALZHEIMER’S DISEASE
Nienke M.E. Scheltens1,2, Sofie Adriaanse1,2, Priscilla P. Oomen1,2, Rik Ossenkoppele1,2,3, Welmoed A. Krudop1,2, Adriaan A. Lammertsma1,2, Frederik Barkhof1,2, Teddy Koene1,2, Charlotte E. Teunissen1,2, Philip Scheltens1,2, Wiesje M. van der Flier1,2, Yolande A.L. Pijnenburg1,2, Bart N.M. van Berckel1,2, 1VU University Medical Center, Amsterdam, Netherlands; 2Neuroscience Campus Amsterdam, Amsterdam, Netherlands; 3 University of California San Francisco, San Francisco, CA, USA. Contact e-mail:
[email protected]
OPERATIONALIZING THE IWG2 AND NIA-AA DIAGNOSTIC CRITERIA FOR ASYMPTOMATIC-AT-RISK FOR ALZHEIMER’S DISEASE OR PRECLINICAL ALZHEIMER’S DISEASE
Gerald P. Novak1, Mark Forrest Gordon2, David Jianjun Li3, Myriam Alexander4, Jo€el Schaerer5, Florent Roche5, Sebastiaan Engelborghs6, Bruno Dubois7, Alzheimer’s Disease Neuroimaging Initiative, European Medical Information Framework for AD, 1Janssen R&D, Titusville, NJ, USA; 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 3Pfizer, Inc., Collegeville, PA, USA; 4Roche Products Limited, London, United Kingdom; 5BioClinica, Inc., Lyon, France; 6Hospital Network Antwerp (ZNA), Antwerp, Belgium; 7 APHP- Groupe Hospitalier Pitie Salpetriere, Paris, France. Contact e-mail:
[email protected]
